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Abstract 
We explored socioeconomic and demographic disparities in breast cancer (BC) stage at 
presentation and survival in a Swiss population-based sample of female BC patients linked to the 
census-based Swiss National Cohort. Tumour stage was classified according to Surveillance, 
Epidemiology and End Results (SEER) Program summary stage (in situ/localized/regional/distant). 
We used highest education level attained to estimate SEP (low/middle/high). Further 
demographic characteristics of interest were age at presentation (30-49/50-69/70-84 years), 
living in a canton with organized screening (yes/no), urbanity of residence (urban/peri-
urban/rural), civil status (single/married/widowed/divorced) and nationality (Swiss/non-Swiss). 
We used ordered logistic regression models to analyse factors associated with BC stage at 
presentation and competing risk regression models for factors associated with survival. Odds of 
later-stage BC were significantly increased for low SEP women (odds ratio (OR) 1.19, 95%CI 1.06-
1.34) compared to women of high SEP. Further, women living in a canton without organized 
screening programme, women diagnosed outside the targeted screening age and 
single/widowed/divorced women were more often diagnosed at later stages. Women of low SEP 
experienced an increased risk of dying from BC (sub-hazard ratio 1.22, 95%CI 1.05-1.43) 
compared to women of high SEP. Notably, these survival inequalities could not be explained by 
socioeconomic differences in stage at presentation and/or other sociodemographic factors. It is 
concerning that these social gradients have been observed in a country with universal health 
insurance coverage, high health expenditures and one of the highest life expectancies in the 
world. 
Page 2 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
3 
Background 
Breast cancer (BC) is the most common cancer in Swiss women. In Switzerland, each year 
approximately 5,700 women are newly diagnosed with BC and the lifetime risk of developing BC 
is almost 13%.
1
 Although mortality has fallen consistently over the last 30 years, BC is the leading
cause of cancer death in Swiss women with approximately 1,400 women dying each year of this 
disease.
1
 Tumour stage at presentation remains one of the major prognostics factors and women
with early-stage BC are expected to have excellent survival rates. In a recent Swiss study, age-
standardized 10-year relative survival varied from 9.3% (Stage IV) to 94.5% (Stage I) depending 
on stage at presentation.
2
Several studies outside of Switzerland have reported negative associations between 
socioeconomic position (SEP) and BC stage at presentation as well as socioeconomic inequalities 
in survival after BC diagnosis.
3
 Socioeconomic and demographic factors may influence access to
health care
4
, cancer awareness
5
 and woman’s attitudes towards preventive methods such as
mammography screening, clinical breast examination and breast self-examination.
6
In Switzerland, health care is organized at the cantonal level, resulting in regional differences in 
provision of cancer prevention and management services.
7
 A Swiss BC pattern of care study, for
example, reported considerable regional variations in early BC detection and treatment.
7
 In
western Switzerland (French-speaking part of the country), organized BC screening programmes 
have gradually been implemented since 1999 for women aged 50 to 69 years, whereas in most 
other regions (German and Italian-speaking parts of Switzerland) only opportunistic screening is 
available.
8
 Consequently, screening uptake varies by canton and region. The Swiss Health Survey 
2012 reports that in 2010-2011, cantons with organized mammography screening had a 68% 
mammogram coverage of women in the recommended screening age (50-69 years), compared 
to 37% in cantons without an organized programme.
9
 Organized BC screening may reduce social 
inequalities in screening uptake
10, 11
, although this has not been consistently observed across 
countries.
12
 
Several studies have identified stage at presentation as an important factor in survival 
differences between socioeconomic groups.
13
 In most studies, however, disparities remained 
after adjustment for stage and other tumour and demographic characteristics.
13
 Remaining 
disparities have been associated with treatment disparities, variations in comorbidities and/or 
additional factors like variations in psychosocial well-being and patients’ support.
13
 In Geneva, 
women with lower SEP were diagnosed with more advanced BC, received more often suboptimal 
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treatment and showed lower cause-specific and overall survival.
14
 A later study in Geneva, 
observed substantial social inequalities in BC management including diagnostic procedures and 
primary treatment.
15
A major goal of health care systems is to equally improve the health in all groups of the 
population they serve.
16
 Despite this aim, socioeconomic and -demographic health inequalities in
BC detection and survival have been observed all over the world
13
, including countries with tax-
funded health care systems designed to provide equal access to care.
17, 18
Swiss data on socioeconomic health inequalities in stage at presentation and survival of BC in 
women is very limited. Therefore, the present study aimed to evaluate socioeconomic and 
demographic disparities in BC stage at presentation and survival in a Swiss population-based 
sample of female BC patients diagnosed between 2001 and 2008.  
Materials and Methods 
Data sources and inclusion criteria 
This study is based on data from the SNC-NICER Cancer Epidemiology Study. The SNC-NICER 
Cancer Epidemiology Study took advantage of the Swiss National Cohort (SNC) and the National 
Institute for Cancer Epidemiology and Registration (NICER) cancer registry network to build a 
comprehensive historical cohort, allowing epidemiologic analysis of factors associated with 
cancer incidence, mortality and survival in Switzerland.  
A detailed description of the SNC can be found elsewhere.
19
 Briefly, 1990 and 2000 census
records were probabilistically linked to cause-specific mortality or emigration records from 1991-
2013 provided by the Federal Statistical Office (FSO). The Swiss census is mandatory and virtually 
complete with a 2000 census estimated coverage of 98.6%.
19
 This study used SNC
sociodemographic information on sex, education level, marital status, place of residence and 
nationality at census date. The coding of the underlying cause of death is federally standardised 
by the FSO. Since 1995, the 10
th
 revision of the international classification of diseases and related 
health problems (ICD-10) has been used following international standards.  
In Switzerland, cancer registration is primarily organized at the cantonal level. The earliest cancer 
registry (CR) data is available from Geneva dating back to 1970, followed by Vaud and Neuchâtel 
(1974), Zurich (1980), St. Gallen-Appenzell (1980), Basel-Stadt and Basel-Landschaft (1981), 
Valais (1989), Graubünden (1989), Glarus (1992), Ticino (1996), Jura (2005) and Fribourg (2006). 
More recently, cancer registration has been introduced in Lucerne (2010), Nidwalden, 
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Obwalden, Uri, Zug (2011), Thurgau (2012), Aargau (2013) and Bern (2014). All CRs implemented 
before 2008 have been requested to participate in the SNC-NICER Cancer Epidemiology Study. 
Seven out of eleven CRs eligible for the study, agreed to participate and provided incidence data 
to the pooled dataset: Fribourg, Geneva, Neuchâtel, Ticino, Valais, Vaud and Zurich. Data from 
these CRs were probabilistically linked to the SNC, including all incident cases starting from the 
date of the census 1990 (or from the implementation of cantonal cancer registration if later) 
through the end of 2008. In 2008, these cantons covered 46.1% of the Swiss population. To 
assess sample representativeness, we compared frequency distributions (age, civil status, 
education, urbanity of residence and nationality) between female residents of participating 
cantons and whole of Switzerland using census 2000 information. Compared to total 
Switzerland, the participating cantons showed distinctly higher proportions of women with 
tertiary education (16.8% versus 11.1%), women living in urban and peri-urban areas (35.3% 
versus 24.7% and 48.8% versus 41.2%, respectively), and women with foreign nationality (22.7% 
vs.15.5%). Cancer registration data used in this study included sex, date of birth, date of cancer 
diagnosis, basis of diagnosis, topography, morphology and behaviour of the tumour, and 
Tumour, Node and Metastasis staging information (TNM).  
The current study population included 17,298 female BC cases (carcinoma in situ and invasive 
BC) first diagnosed between Census 2000 (5
th
 of December 2000) and 31
st
 of December 2008.
TNM codes were based on the fifth and sixth TNM editions. The Census 2000 was used as 
starting point as for previous time periods, the proportion of missing stage information was high 
(up to >25%) in two cantons. Education was used as a proxy for SEP so young women (< 30 years 
of age at diagnosis, N=46) and women with missing education information (N=147) were 
excluded from the study population. In addition, women diagnosed at 85 years of age or older 
were excluded (N=936) because data quality (percentage of death certificate only cases [%DCO] 
8.2%, histologically verified cases 78.4%) and completeness of stage information (60.1%) was low 
in this age group. The study population showed %DCO of 0.4% indicating high completeness of 
case ascertainment with 98.3% of the cases histologically verified and 94.8% with sufficient TNM 
information to classify tumour stage.  
Stage at presentation analyses were based on data from a subset of cantonal cancer registries 
(Geneva, Valais, Zurich) that provided breast carcinoma in situ cases (N=10,915). In a 
supplemental analysis, stage at presentation calculations were repeated and limited to invasive 
BCs to enable the inclusion of all participating cancer registries (Suppl. Table 1). The 
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supplemental analysis followed survival analyses were based on invasive cancers including all 
participating cancer registries (16,296). 
Analytic methods 
Surveillance, Epidemiology and End Results (SEER) Program summary stage was calculated based 
on the TNM classification system following the algorithm for mapping stage at diagnosis from 
TNM to SEER summary stage as described by Walters et al.
20
 We used SEER summary stage
instead of the more detailed TNM staging system due to extensive and significant revision in BC 
staging between the fifth and sixth TNM edition.  
We prioritized pathological T and N over clinical T and N. Missing M or Mx were assumed to be 
equivalent to M0. If clinical and pathological M was available, any indication of metastasis was 
prioritized. Pathological and clinical T and N information was available in 84.1% and 46.0% of all 
invasive BC cases, respectively. The proportion of cases with missing M or Mx was 26.4%. 
Overall, tumour stage could be calculated for 94.9% of all invasive BC cases. Carcinoma in situ 
cases have been identified based on the ICD-O-3 behaviour code.  
We used highest education level attained by the woman to estimate SEP (compulsory education 
or less: low SEP, secondary education: middle SEP, tertiary education: high SEP).  
We descriptively investigated stage at presentation by SEP, age-group (30-49, 50-69, 70-84 
years) and residence (canton with
 
or without organized screening). Ordered logistic regression 
models examined the association between cancer stage at presentation and SEP. We calculated 
three models using the following variables as predictors for stage at presentation: (model 1) SEP; 
(model 2) model 1 plus age at presentation (30-49, 50-69, 70-84 years), civil status (30-49, 50-69, 
70-84 years) and nationality (Swiss, non-Swiss); (model 3) model 2 plus urbanity of residence and 
canton with or without organized screening programme. The third model has been additionally 
adjusted for canton of residence. No significant interactions were observed, therefore, we only 
included main effects in the final model.  
For women within the recommended screening age, we conducted a sub-analysis of Valais and 
Geneva, the only two cantons which both, offered organized screening during the study period 
and provided carcinoma in situ cases to the study population. We examined the association 
between being diagnosed within or outside the organized programme and SEP using logistic 
regression including civil status and nationality and canton of residence as covariates. 
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Survival was analysed using competing risk regressions based on Fine and Gray's proportional 
hazard model.
21
 All underlying causes of death other than BC were classified as competing risks.
Four models have been calculated using the following variables as predictors: (model 1) SEP; 
(model 2) model 1 plus age at presentation, civil status and nationality; (model 3) model 2 plus 
stage at presentation; and (model 4) model 3 plus urbanity of residenc and canton with or 
without organized screening programme. Results of survival analyses are reported as sub-hazard 
ratios of death due to BC (SHRs) with 95% confidence intervals (95%CI).  
Both final models (stage at presentation and survival analyses) have been additionally adjusted 
for canton of residence to account for unmeasured canton characteristics associated with SEP 
distribution and stage at diagnosis/survival.   
All analyses were performed using the statistical software package Stata, version 13.1 for 
Windows (StataCorp, College Station, Texas). 
Results 
Patient characteristics by SEP cases included in stage at presentation and survival analyses are 
listed in Table 1. Incident breast carcinoma cases (Ntotal=10,915, Nstaged=10,362) by cancer 
registry included in stage at presentation analyses is shown in Suppl. Table 2. Incident BC cases 
(Ntotal=16,296; Nstaged=15,462) and person-years (PY) (PYstotal=127,040; PYstaged=121,553) by 
cancer registry included in survival analyses is shown in Suppl. Table 3.  
BC stage at presentation 
In the unadjusted model, odds ratios (ORs) of later stage at BC diagnosis were significantly 
increased for women of middle (OR 1.18, 95%CI 1.07-1.31) and low SEP (OR 1.30, 95%CI 1.16-
1.46) compared to women of high SEP (Table 2). After adjustment for demographic factors 
(model 2) and area of living (urbanity of residence, canton with/without organized screening, 
canton of living) (model 3), ORs for middle SEP women and low SEP women decreased to 1.09 
(95%CI 0.99-1.21) and 1.19 (95%CI 1.06-1.34), respectively. In the final model, women living in a 
canton without an organized screening programme were also more likely to have their BC 
diagnosed at a later stage (OR 1.42, 95%CI 1.30-1.55). Further, women outside the targeted 
screening age (30-49 years: OR 1.22, 95%CI 1.11-1.33; 70-84 years OR: 1.31, 95%CI 1.19-1.45) 
and single/widowed/divorced women showed elevated risks for later stages at diagnosis (OR 
1.12 (95%CI 0.99-1.27) - 1.14 (95%CI 1.02-1.27)).  
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4.12, 95%CI 3.66-4.63; distant stage: SHR 27.27, 95%CI 23.67-31.41). Compared to women 
diagnosed in the recommended screening age (50-69 years), women aged 70-84 years showed 
an elevated risk of BC death (SHR 1.34, 95%CI 1.19-1.50). For women aged 30-49 years, a 
reduced risk was observed (SHR 0.76, 95%CI 0.66-0.86). Living in a canton without an organized 
screening was associated with an increased SHR (SHR 1.44, 95%CI 1.23-1.68) even after 
adjustment for stage at diagnosis. Further, living in a non-urban region was associated with an 
increased risk of BC death with SHRs of 1.13 (95%CI 1.02-1.26) (peri-urban region) and 1.21 
(95%CI 1.03-1.41) (rural region). Residents of foreign nationality were at lower risk of dying from 
their BC (SHR 0.84, 95%CI 0.73-0.98). We observed no statistically significant effects for civil 
status in the fully adjusted model (Table 3).  
Discussion 
Summary of main findings 
Despite universal health insurance coverage
22
, high health expenditures
22
, the highest average
household net financial wealth worldwide
23
 and one of the highest life expectancies in the
world
24
, high risk groups for later-stage BC and lower BC survival were identified in Switzerland.
In our study, women of lower SEP, unmarried women, women below (<50 years) or above (>69 
years) the recommended screening age, and women living in a canton with no organized BC 
screening programme showed an increased risk of being diagnosed with a later-stage BC. In 
addition, women of lower SEP experienced poorer disease-specific survival. Notably, these 
survival inequalities could not be explained by socioeconomic differences in stage at 
presentation and/or other sociodemographic factors such as age, nationality and civil status. 
Discussion in the context of the literature 
Our Swiss results are in line with international data, showing that lower SEP is associated with 
later-stage BC and shortened survival.
3
 Much of the deprivation gap in survival can be attributed 
to inequalities in stage at presentation, the most important single predictor for BC survival.
13, 25
 
However, in most research socioeconomic survival gaps remained in stage-stratified analyses or 
after adjustment for stage at diagnosis.
13, 25
 Further, socioeconomic inequalities for BC stage and 
survival were observed in various countries irrespective of the measurement used for SEP 
classification (e.g. education, occupation, income, area-based deprivation index).
13
 Possible 
reasons for the delayed BC diagnosis in lower SEP women might be related to inequalities in 
health care access
4
, cancer awareness
5
 and/or attitudes towards cancer (e. g. cancer fatalism).
6
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All these factors might substantially contribute to observed disparities in BC screening uptake
11,
26
, and/or cancer-related health behaviour such as health care seeking after detection of first 
symptoms (patient-mediated delay).
27
 Essentially, equal access to health care goes beyond 
universal health insurance coverage and adequate provision of accessible health services (such 
as provision in proximity of the patient's residence).
28
 Additional factors such as language
barriers, uncovered costs (travel costs, childcare during consultation/treatment) or previous 
negative health care experiences might hamper health care access of individuals and specific 
social groups.
29
 Disparities in cancer awareness might have also influenced the results. In a
Danish study, for example, lower SEP was associated with less awareness of BC symptoms and 
risk factors.
5
 Further, fatalistic attitudes towards cancer have been shown to be associated with
lower SEP
6, 30
, whereas cancer fatalism in turn was associated with being less positive about early
detection and being more fearful about seeking help for suspicious symptoms.
30
 In our study, we
observed a social shift towards higher proportions of carcinoma in situ cases for women in the 
recommended screening age only in cantons offering organized screening. In the canton without 
organized screening, proportions of carcinoma in situ cases were fairly equal across SEP groups, 
similar to those observed in low SEP women in cantons with organized screening. As carcinoma 
in situ are rare in the symptomatic setting, observed variations were most likely caused by 
differences in mammography screening use (organized and/or opportunistic). In the canton 
without organized screening programme, social inequalities in early detection were mainly 
visible for localized BC indicating that in this canton other factors such as inequalities in cancer 
awareness/knowledge, health care access and /or help seeking behaviour after detection of 
symptoms might have led to the observed results.  
In our study, socioeconomic inequalities in survival remained after adjusting for stage at 
presentation suggesting that further factors such as treatment disparities and/or variations in 
comorbidities might play a role. This assumption is supported by the findings in the canton of 
Geneva, where lower SEP women were more likely to receive suboptimal treatment compared 
to their more affluent counterparts.
14, 15
  
In women aged 70-84 years, lower SEP was associated with an increased proportion of unstaged 
BCs. However, a clear social gradient was only apparent in the cantons with organized screening 
programmes. Women 85 years and older were excluded from the analyses because of the high 
proportion with missing stage information despite the fact that tumour stage should be 
investigated (at least clinically) in all women with BC.
31
 However, a distinction must be made 
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between a true lack of stage information and a lack of reporting stage.
32
 A true lack of staging 
might occur in patients with very limited life expectancy (severe comorbidities, high age)
32, 33
 or
due to patients’ choice.
32, 34
 In contrast, lack of reporting refers to cases where clinical and/or 
pathological stage has been investigated but has not been captured by the cancer registry. A 
study investigating the completeness of BC staging in the New Zealand Cancer Registry, found 
that 12% of staged BC cases were recorded as unknown stage in the cancer registry system.
32
Although observed socioeconomic inequalities in diagnostic assessment might be – at least 
partly – explained by the fact that comorbidities are more common in lower SEP women and in 
older women.
35
Biennial mammography coverage in the recommended screening age was substantially higher in 
cantons with an organized programme (located in the western, French-speaking region of 
Switzerland) compared to cantons without organized programme.
9
 However, the participation
rate in the organized programmes varied substantially across cantons. In 2004, screening 
coverage in the organized programme of women aged 50-69 years was 23% in Geneva compared 
to 66% in Valais.
36
 Importantly, opportunistic screening has widely been offered concomitantly
to organized programmes in Switzerland.
36
 A prospective study in Geneva reported that only
12% of women invited to screening were screened within the organized programme and 39% 
received screening outside of the framework of the organized programme.
10
 Therefore, the
lower participation rate in the Geneva programme likely reﬂects a higher prevalence of 
opportunistic screening rather than real differences in mammography coverage.
37
  
In our analyses, the cantons with organized BC screening programmes showed a shift towards 
earlier stages in women aged 50 years and older compared to the canton without an 
implemented programme. A similar shift – albeit less pronounced – has been observed for 
younger women below the recommended screening age indicating that younger women in 
cantons with organised screening are more likely to undergo mammography screening than their 
counterparts in cantons without a programme.  
Women outside the recommended screening age showed an increased risk of being diagnosed 
at later stages. For the time period under investigation, the recommended screening age in 
Switzerland was 50-69 years. The age-cut was based on the fact that at this time the most 
convincing evidence for a beneficial effect available from randomized controlled trials existed for 
women aged 50-69 years. However, women older than 69 years were allowed to continue 
screening within the organized program if desired and if no major comorbidities existed.
36
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Diagnosing BC by mammography is more difficult in younger women because their breast tissue 
is denser making it hard to detect anomalies - the main reason why mammography screening is 
not recommended for younger women.
36
 BC in younger women has been shown to be more 
aggressive
38
 and have a less favourable prognosis
39
, although the latter has not been consistently 
observed.
40
 In our study, we observed an increased survival for women below the age of 50
years compared to their older counterparts (overall and adjusted for stage at presentation). An 
earlier Swiss study found that women with BC diagnosed below the age of 40 years had 
substantially lower survival than women diagnosed between the age of 40-49 years.
39
 Due to the
small number of cases below the age of 40 years we categorised younger women as < 50 years 
thus potential survival disadvantages in the very young women could not be examined in this 
study.  
Several studies outside of Switzerland observed beneficial impacts of being married in regard to 
BC stage at presentation and survival after BC
13, 41
, indicating that social support might have a
significant impact on cancer detection, treatment and survival.
41
 A study in the United States
observed that unmarried women were at higher risk of being diagnosed with metastatic cancer, 
under-treatment and death resulting from their cancer.
41
 In our study, we observed an increased
risk for unmarried women for being diagnosed with later stage BC (albeit not reaching 
significance for widowed women). For survival after BC, we observed a significantly lower 
survival only in single women and only if not adjusted for stage at diagnosis. In this study marital 
status was obtained from the census and with increasing time between date of census and end 
of follow-up, marital status might have changed leading to misclassification when referring to 
the time of or after diagnosis.  
In our study, women living in non-urban regions showed lower survival compared to their urban 
counterparts. Factors that may mediate these disparities may include inequalities in tumour 
characteristics (i.e. stage at presentation), patients’ treatment preferences and adherence, 
and/or access to and quality of care received. However, in our study we did not observe 
significant disparities in stage at presentation between the rural and urban population 
suggesting that differences in early-detection played a minor role.  
Compared to women with Swiss nationality, our results suggest that women of foreign 
nationality have an overall and stage-specific survival benefit. A potential explanation for these 
differences is the so-called “healthy migrant effect”. The healthy migrant effect describes an 
empirically observed mortality advantage of migrants relative to the population in the host 
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country due to self-selection of migrants who tend to differ from their fellow countrymen in 
respect to education, risk exposure or health, leading to better health outcomes despite 
potential social inequalities and discrimination in the host country. However, data quality issues 
might have affected the results in this study. Death records of non-Swiss residents showed an 
increased probability of not being linked to census data compared to death records of Swiss 
nationals
19
 and (undocumented) out-migration may have led to incomplete mortality follow-up,
especially in semi-skilled or unskilled migrant workers, who tend to leave the home country 
when they are sick or disabled.
42
 Additionally, it is difficult to draw conclusions for the non-Swiss
population because it is a highly heterogeneous group. Non-Swiss have different countries of 
origin, migration status (first, second or third generation immigrants), type of residence permit, 
level of education, employment and income, to name a few. Hence, this topic should be 
investigated further in future studies.  
Strengths and Limitations 
This is the first Swiss study investigating socioeconomic inequalities of BC stage at presentation 
and survival, combining data from multiple Swiss cantons and from a national census. Overall, 
the study population had less than 0.5% DCO cases indicating a high completeness of case 
ascertainment. In the age-group under investigation, stage information was available for 95% of 
all cases. 
Our study has some limitations.  First,  the meaning and consequences of educational attainment 
might vary by birth cohort.
43
 However, there is considerable international evidence that 
education is strongly associated with health, health behaviour and preventive service use and 
that a substantial share of these effects are of causal origin.
44
 In addition, individual education is
generally stable beyond early adulthood whereas civil status and living conditions are more likely 
to change over time and individual education level was virtually complete (>99%) in the study 
population. In a preceeding analysis, we compared three indicators of SEP in relation to stage at 
presentation: (1) education woman - highest education level attained by the woman 
(compulsory or less, upper-secondary, upper-tertiary education), (2) education couple – if 
married, highest education level attained by the woman or spouse, and (3) quintiles of the Swiss 
neighbourhood index (Swiss-SEP), a composite area-level SEP measure based on income, 
education, occupation and housing conditions.
45
 Regardless of SEP indicator used, we observed 
comparable patterns and effects for SEP and the covariates included in the models
46
, although 
importantly, each indicator of SEP measures different aspects of socioeconomic stratification.
43 
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Overall, only 7 out of 26 Swiss cantons participated in the study covering around 46% of the 
population. Further, stage at presentation analyses were restricted to cantonal cancer registries 
providing carcinoma in situ cases diminishing population coverage for these analyses to 27%. The 
resulting study sample was not representative for the female Swiss population with respect to 
SEP, urbanity or residence and nationality. Importantly, there may be also other unmeasured 
cantonal/regional characteristics associated with stage at presentation and/or survival that could 
impact the results. Therefore, we additionally adjusted for canton of residence in the final 
models. Generalisability of these finding, although better than previous publications, remains 
limited by the lack of cantonal cancer registry participation and should be made with caution. 
Another weakness of the study is the lack of more detailed tumour characteristics ((morphologic 
subtype, grade, oestrogen receptor (ER) status, progesterone-receptor (PR) status, human 
epidermal growth factor receptor 2 (HER2/neu) and other prognostic factors such as 
comorbidities and cancer treatment. From studies outside of Switzerland, it is known that 
morphological type of BC and ER status might vary between social groups.
13
 A Swiss study
conducted in Geneva reported variations depending on SEP for stage at presentation and 
morphological BC type, but not for grade, tumour size and ER status.
14
 Substantial treatment
differences between social groups have been also been reported for this canton.
14, 15
 Additional
analysis of morphological type by SEP (not presented) suggests that morphological differences 
reported from Geneva might be largely the result of varying proportions of cases with unknown 
morphological type (classified as other morphological type in their analyses) rather than 
reflecting real morphological differences between social groups. Further, stage at presentation 
has been consistently shown to be a major predictor of BC survival and other tumour 
characteristics contributed much less to the explanation of the observed survival experience.
13
  
Comorbidities are more common in lower SEP women and may have an adverse impact on 
cancer survival.
35
 Comorbidities might be associated with less complete diagnostic assessment 
including biopsy for staging
32, 33
, limited treatment options, and a decreased likelihood to receive 
treatment with curative intent
47
. Further, SEP might influence patients treatment choice
48
 
and/or adherence to treatment
49
. However, studies in the canton of Geneva suggest that 
observed survival inequalities after BC are – at least partly – caused by differences in care 
management depending on SEP.
14, 15
 Unfortunately, information on comorbidities were not 
available for this study.  
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Since the introduction of BC screening programmes, the usefulness of mammography screening 
has been questioned. Critics argue that screening-induced over-diagnosis and its consequences 
outbalance potential mortality benefits.
50
 Consequently, our analyses might be affected by 
higher proportions of over-diagnosis in the cantons with implemented screening programme 
resulting in higher mammography screening coverage. 
Finally, we used the SEER basic summary staging because substantial TNM classification changes 
over the investigated time period prevented the use of the more detailed TNM-staging. A more 
detailed staging system might have shown stronger effects. 
Conclusions 
Characteristics associated with later stage BC diagnosis in Switzerland were lower SEP, being 
unmarried, being outside of the recommended screening age and living in a canton without an 
organized BC screening programme. In addition, women of lower SEP experienced poorer 
disease-specific survival. Notably, these survival inequalities could not be explained by 
socioeconomic differences at stage of presentation and/or other sociodemographic factors such 
as age, nationality and civil status. Appropriate intervention strategies are needed to reduce 
socioeconomic and demographic health inequalities in women with BC. 
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Table 1: Patient characteristics by socioeconomic position (SEP). (1) Carcinoma in situ and invasive breast 
cancer cases from three Swiss cancer registries (CRs) for stage at presentation analyses. (2) Invasive 
breast cancer cases from seven Swiss cancer registries (CRs) for survival analyses. 
Analysis of SEP and 
stage at presentation 
Low SEP    Middle SEP High SEP Total 
N column % N column % N column %  N column %  
(1) Stage at presentation analyses (N=10,915) 
Stage at presentation 
in situ 217 7.3 574 9.6 211 11.0 1,002 9.2 
Local 1,382 46.3 2,780 46.3 951 49.4 5,113 46.8 
Regional 1,036 34.7 2,139 35.6 625 32.5 3,800 34.8 
distant 142 4.8 239 4.0 66 3.4 447 4.1 
unknown stage 206 6.9 275 4.6 72 3.7 553 5.1 
Age at presentation 
<50 years 435 14.6 1,340 22.3 590 30.7 2,365 21.7 
50-69 years 1,433 48.0 3,296 54.9 1,090 56.6 5,819 53.3 
69-84 years  1,115 37.4 1,371 22.8 245 12.7 2,731 25.0 
Civil status 
single 242 8.1 750 12.5 388 20.2 1,380 12.6 
married 1,766 59.2 3,785 63.0 1,146 59.5 6,697 61.4 
widowed 638 21.4 632 10.5 115 6.0 1,385 12.7 
divorced 337 11.3 840 14.0 276 14.3 1,453 13.3 
Nationality 
Swiss  2,270 76.1 5,455 90.8 1,548 90.8 9,273 85.0 
non-Swiss 713 23.9 552 9.2 377 9.2 1,642 15.0 
Urbanity of residence 
urban 1,225 41.1 2,157 35.9 840 43.6 4,222 38.7 
peri-urban 1,326 44.5 3,417 56.9 1,015 52.7 5,758 52.8 
rural  432 14.5 433 7.2 70 8.6 935 8.6 
Living in an region with organized breast cancer screening 
Yes
1
 1,457 48.8 1,990 33.1 994 51.6 4,441 40.7 
No
2
 1,526 51.2 4,017 66.9 931 48.4 6,474 59.3 
Total    N     row % 2,983 27.3 6,007 55.0 1,925 17.6 10,915 100.0 
(2) Survival analysis (N=16,296) 
Stage at presentation 
Local 2,507 51.4 4,633 53.4 1,535 56.1 8,675 53.2 
regional 1,778 36.5 3,254 37.5 982 36.0 6,014 36.9 
Distant 267 5.5 396 4.6 110 4.0 773 4.7 
unknown stage 326 6.7 400 4.6 108 4.0 834 5.1 
Age at presentation 
<50 years 608 12.5 1,958 22.6 818 29.9 3,384 20.8 
50-69 years 2,252 46.2 4710 54.2 1,566 57.3 8,528 52.3 
70-84 years  2,018 41.4 2,015 23.2 351 12.8 4,384 26.9 
Civil status 
Single 387 7.9 1,115 12.8 527 19.3 2,029 12.5 
Married 2,838 58.2 5,483 63.2 1,659 60.6 9,980 61.2 
widowed 1,106 22.7 918 10.6 175 6.4 2,199 13.5 
divorced 547 11.2 1,167 13.4 374 13.7 2,088 12.8 
Nationality 
Swiss  3,788 77.7 7,878 90.7 2,211 80.8 13,877 85.2 
non-Swiss 1,090 22.4 805 9.3 524 19.2 2,419 14.8 
Urbanity of residence 
urban 1,852 38.0 2,949 34.0 1,059 38.7 5,860 36.0 
peri-urban 2,088 42.8 4,731 54.5 1,435 52.5 8,254 50.7 
rural  938 19.2 1,003 11.6 241 8.8 2,182 13.4 
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Living in a canton with organized breast cancer screening 
Yes
3
 2,600 53.3 3,828 44.1 1,588 58.1 8,016 49.2 
No
4
 2,278 47.7 4,855 55.9 1,147 41.9 8,280 50.8 
Vital status at end of follow-up 
Alive 3,277 67.2 6,819 78.5 2,258 82.6 12,354 75.8 
Dead 1,510 31.0 1,780 20.5 423 15.5 3,713 22.8 
lost-to-follow-up 91 1.9 84 1.0 54 2.0 229 1.4 
Total    N     row % 4,878 29.9 8,683 53.3 2,735 16.8 16,296 100,0 
Note: For stage analyses, 92 cases (0.8%) out of originally 11,007 cases have been excluded due to missing SEP information. For survival analyses 147 cases (0.9%) out of originally 
16,516 cases have been excluded due to missing SEP information. From the remaining dataset, 73 additional cases were excluded due to zero survival time (death certificate only 
cases or cases first diagnosed at autopsy). 
1
Geneva, Valais; 
2
Zurich; 
3
Fribourg, Geneva, Valais, Vaud; 
4
Neuchâtel, Ticino, Zurich. In Neuchâtel, an organized screening programme was implemented in 2007. Incident cases of
the years 2007 and 2008 were excluded from analyses.  
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Figure 1: Distribution of breast cancer stage at presentation by socioeconomic position (SEP), age-group and canton of 
residence (canton with organized mammography screening: Geneva, Valais; canton without organized mammography 
screening: Zurich). 
7.8
51.8
33.7
3.6
3.1
11.0
45.9
36.1
3.9
3.0
10.0
49.5
33.1
4.3
3.0
9.3
55.4
28.7
4.2
2.5
11.9
53.1
29.5
3.3
2.3
15.0
54.4
26.4
2.22.0
4.3
46.5
32.3
5.7
11.4
7.9
50.9
30.2
4.3
6.6
11.2
50.5
28.0
5.6
4.7
9.9
40.9
46.3
2.10.8
10.9
39.1
43.6
3.1
3.3
10.0
43.3
42.3
1.03.4
8.5
43.4
40.0
4.8
3.3
9.8
47.2
36.0
3.8
3.3
8.2
48.4
35.7
4.2
3.6
4.5
38.7
34.4
6.1
16.2
5.3
40.9
36.8
6.0
10.9
5.8
44.9
29.0
7.2
13.0
0
20
40
60
80
100
0
20
40
60
80
100
low SEP middle SEP high SEP low SEP middle SEP high SEP low SEP middle SEP high SEP
low SEP middle SEP high SEP low SEP middle SEP high SEP low SEP middle SEP high SEP
organized screening, age <50 organized screening, age 50-69 organized screening, age 70-84
no organized screening, age <50 no organized screening, age 50-69 no organized screening, age 70-84
in situ local regional distant unknown stage
p
e
rc
e
n
t
Page 21 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
22 
Table 2: Odds ratio (OR) of later stage at breast cancer at presentation: Carcinoma in situ and invasive breast cancer 
cases from three Swiss cancer registries (CRs)  
Model 1 Model 2 Model 3 
OR [95%CI] OR [95%CI] OR [95%CI] 
SEP 
High SEP (ref.) 
Middle SEP 1.18 [1.07-1.31] 1.17 [1.05-1.29] 1.09 [0.99-1.21] 
Low SEP 1.30 [1.16-1.46] 1.25 [1.12-1.41] 1.19 [1.06-1.34] 
Age at presentation 
50-69 years (ref.) 
30-49 years 1.24 [1.13-1.36] 1.22 [1.11-1.33] 
70-84 years 1.41 [1.27-1.55] 1.31 [1.19-1.45] 
Civil status 
married (ref.) 
single 1.14 [1.01-1.27] 1.13 [1.01-1.27] 
widowed 1.13 [1.00-1.28] 1.12 [0.99-1.27] 
divorced 1.18 [1.06-1.32] 1.14 [1.02-1.27] 
Nationality 
Swiss (ref.) 
Non-Swiss 0.97 [0.87-1.07] 0.97 [0.88-1.08] 
Urbanity 
urban (ref.) 
peri-urban 0.93 [0.86-1.01] 
rural 0.98 [0.84-1.14] 
Organized screening
1
yes (ref.) 
no 1.42 [1.30-1.55] 
Three models have been calculated using the following variables as predictors: (model 1) SEP; (model 2) model 1 plus age at presentation, civil 
status and nationality; (model 3) model 2 plus canton with or without organized screening programme and urbanity of residence. The third model 
has been additionally adjusted for canton of residence.
 
1
Cantons with organized screening: Geneva, Valais; canton without organized screening: Zurich.  
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Table 3: Subhazard ratios and 95% confidence intervals (95%CI), competing risk survival after breast 
cancer in Swiss women 
Model 1 Model 2 Model 3 Model 4 
SHR [95%CI] SHR [95%CI] SHR [95%CI] SHR [95%CI] 
SEP 
High SEP (ref.) 
Middle SEP 1.20 [1.06-1.37] 1.13 [0.99-1.29] 1.06 [0.92-1.22] 1.01 [0.88-1.16] 
Low SEP 1.60 [1.40-1.83] 1.39 [1.21-1.61] 1.29 [1.11-1.50] 1.22 [1.05-1.43] 
Age at 
presentation 
50-69 years 
(ref.) 
30-49 years 0.84 [0.74-0.95] 0.77 [0.67-0.87] 0.76 [0.66-0.86] 
70-84 years 1.48 [1.33-1.64] 1.31 [1.17-1.47] 1.34 [1.19.1.50] 
Civil status 
married (ref.) 
single 1.24 [1.09-1.42] 1.14 [0.99-1.31] 1.16 [1.00-1.33] 
widowed 1.10 [0.97-1.25] 1.09 [0.95-1.26] 1.09 [0.94-1.26] 
divorced 1.02 [0.89-1.17] 0.94 [0.82-1.09] 0.97 [0.83-1.12] 
Nationality 
Swiss (ref.) 
Non-Swiss 0.82 [0.72-0.94] 0.80 [0.69-0.92] 0.84 [0.73-0.98] 
Stage at 
presentation 
local (ref.) 
regional 4.21 [3.75-4.74] 4.12 [3.66-4.63] 
distant 26.92 [23.39-30.98]] 27.27 [23.67-31.41] 
Urbanity 
urban (ref.) 
peri-urban 1.13 [1.02-1.26] 
rural 1.21 [1.03-1.41] 
Organized 
screening 
yes (ref.) 
no 1.44 [1.23-1.68] 
Survival was analysed using competing risk regressions based on Fine and Gray's proportional hazard model 
21
. All underlying causes of death 
other than breast cancer were classified as competing risks. Four models have been calculated using the following variables as predictors: (model 
1) SEP; (model 2) model 1 plus age at presentation, civil status and nationality; (model 3) model 2 plus stage at presentation; and (model 4) 
model 3 plus canton with or without organized screening programme and urbanity of residence. The fourth model has been additionally adjusted 
for canton of residence. Results are reported as sub-hazard ratios for breast cancer survival (SHRs) with 95% confidence intervals (95%CI).  
1
Cantons with organized screening: Fribourg, Geneva, Valais, Vaud; 
 
cantons without organized screening: Neuchâtel, Ticino, Zurich. In Neuchâtel, 
an organized screening programme was implemented in 2007. Incident cases of the years 2007 and 2008 were excluded from analyses.  
Page 23 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
